Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)

NCT01569152 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG: MK-8457 100 mg
DRUG: Dose-Matched Placebo
DRUG: Methotrexate

Sponsor

Merck Sharp & Dohme LLC